Toledano Miranda Jayne 4

4 · Entera Bio Ltd. · Filed Jul 16, 2026

AI-generated summary of this filing

Updated Jul 16, 2026

Entera Bio (ENTX) CEO Jayne Toledano Receives RSU Awards

What Happened

Jayne Toledano, CEO of Entera Bio Ltd. (ENTX), was awarded a total of 420,560 stock-settled restricted stock units (RSUs) on July 14, 2026. The grant consists of 347,567 RSUs (in lieu of her 2025 annual cash bonus) and 72,993 RSUs (in lieu of $100,000 of 2026 base salary). Each award is shown at $0.00 per share in the filing because these are compensation awards, not open-market purchases.

Key Details

Transaction date: July 14, 2026; Form 4 filed July 16, 2026 (appears timely).
Shares/units awarded: 347,567 RSUs (F1) + 72,993 RSUs (F2) = 420,560 RSUs total; acquisition price reported $0.00.
Shares owned after transaction: Not specified in the provided filing excerpt.
Material footnotes: Grants were approved by the Board on May 7, 2026 and approved by shareholders on July 14, 2026. RSUs vest ratably quarterly over a one-year period beginning May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Transaction type: Award/Grant (code "A"); these RSUs convert to ordinary shares as they vest (not an immediate sale).

Context

These awards are compensation-related (awarded in lieu of cash) and are not the same signal as an insider buying shares; they increase the CEO’s potential future ownership as the RSUs vest. Because vesting is spread over one year (and can accelerate on a Change in Control), the economic impact to the CEO is realized over time rather than immediately.

Form 4

Period: 2026-07-14

DirectorChief Executive Officer

Transactions

Award
Ordinary Shares, par value NIS 0.0000769 per share
[F1]
2026-07-14+347,567→ 774,142 total
Award
Ordinary Shares, par value NIS 0.0000769 per share
[F2]
2026-07-14+72,993→ 847,135 total

Footnotes (2)

[F1]Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2025 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
[F2]Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2026. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Signature

/s/ Dana Yaacov-Garbeli, Attorney-in-Fact|2026-07-16

1 file